Site-specific action of l -3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic l -3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats

• Published in: Neuroscience Vol. 166; no. 2; pp. 355 - 358
• Main Authors: Buck, K, Voehringer, P, Ferger, B
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Ltd 17.03.2010; Elsevier
• Subjects: Animals; Basal ganglia; Biological and medical sciences; Corpus Striatum - drug effects; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; dyskinesia; Dyskinesia, Drug-Induced; Fundamental and applied biological sciences. Psychology; GABA; Globus Pallidus - drug effects; glutamate; in vivo microdialysis; l-dihydroxyphenylalanine; Levodopa - pharmacology; Male; Medical sciences; Microdialysis; Neurology; Oxidopamine; Parkinson's disease; Rats; Rats, Wistar; Substantia Nigra - drug effects; Vertebrates: nervous system and sense organs; Parkinson's disease; substantia nigra pars reticulata; l-dihydroxyphenylalanine; 6-OHDA; GP; l-3,4-dihydroxyphenylalanine; STN; dyskinesia; artificial cerebrospinal fluid; 6-hydroxydopamine; PD; SNr; subthalamic nucleus; GABA; aCSF; l-DOPA; in vivo microdialysis; DA; dopamine; globus pallidus; glutamate; Rat; Central nervous system; L-dihydroxyphenylalanine; Parkinson disease; Oxidopamine; Pallidum; Site of action; Encephalon; Degenerative disease; Nervous system diseases; Rodentia; Basal ganglion; Corpus striatum; Glutamate; Cerebral disorder; Vertebrata; Chronic; Mammalia; Locus niger; Microdialysis; Animal; Central nervous system disease; Excitatory aminoacid; Neurotransmitter; Lesion; Dopa; Extrapyramidal syndrome
• ISSN: 0306-4522; 1873-7544
• DOI: 10.1016/j.neuroscience.2009.12.032

Abstract Dyskinesia eventually develops in the majority of Parkinson's disease patients treated with l -3,4-dihydroxyphenylalanine ( l -DOPA). We have investigated the effect of an acute and local administration of l -DOPA, GABA and glutamate to provoke dyskinetic movements in three basal ganglia structures (striatum, globus pallidus (GP) and substantia nigra pars reticulata (SNr)) of chronically l -DOPA-treated, unilaterally 6-hydroxydopamine-lesioned rats. We demonstrated that l -DOPA administration into the lesioned striatum using the technique of reverse in vivo microdialysis was an effective trigger to switch on dyskinesia. Notably, local l -DOPA perfusion at the same concentration in the ipsilateral GP and SNr did not provoke significant dyskinetic behaviour. Neither GABA nor glutamate triggered dyskinetic movements in the striatum, GP or SNr. We postulate a site-specific action of l -DOPA for the evocation of already established dyskinesia since l -DOPA in the striatum but not in the GP or SNr switched on dyskinetic behaviour.